Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.
Fractyl Health's Revita procedure shows promise in maintaining weight after stopping GLP-1 drugs, with new six-month data prompting the company to seek a streamlined FDA pathway. A packed 2026 roadmap aims for a U.S. submission, but financial pressures loom.
Truist Securities has increased its price target for Nuvation Bio, highlighting the promising early commercial traction of its oncology drug Ibtrozi, which is outpacing competitors in the ROS1 inhibitor space.
While Wall Street chases the latest weight-loss drug headlines, Novo Nordisk's recent launch of an oral GLP-1 therapy and its entrenched insulin business present a compelling value proposition for long-term investors.
Philadelphia District Attorney Larry Krasner faces mounting pressure and bipartisan condemnation after publicly threatening to 'hunt down' ICE agents, comparing them to Nazis. A Republican congressman has formally urged the Justice Department to open a criminal investigation into the remarks.
Synthetic biology leader Twist Bioscience reported strong Q1 FY2026 results, with revenue climbing 17% year-over-year to $103.7 million. Management highlighted accelerating demand from AI-powered drug discovery and reiterated its path to adjusted EBITDA breakeven by Q4 FY2026.
The trial of Marius Borg Høiby, son of Crown Princess Mette-Marit, opens in Oslo, exposing a profound crisis for the Norwegian monarchy as he faces charges including rape and assault.
Political scientist Laura Fernandez Delgado has won Costa Rica's presidency outright in the first round, becoming the nation's second female leader and pledging to deepen the economic policies of the outgoing administration amid challenges of crime and a divided legislature.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
A suspected human smuggler with a prior conviction was shot by federal agents near the Arizona-Mexico border after allegedly firing at a CBP helicopter and agents during a foot pursuit, according to law enforcement officials.
Marius Borg Høiby, the eldest son of Crown Princess Mette-Marit, was taken into custody on fresh allegations of assault and weapons offenses just days before his high-profile trial on multiple rape charges is set to begin, deepening the crisis for Norway's monarchy.
Harmony Biosciences CFO Sandip Kapadia has liquidated his entire direct stake in the company, a move that contrasts sharply with the firm's robust financial performance and bullish $1 billion revenue target for its flagship drug WAKIX by 2026. While the sales were pre-planned, the timing fuels debate on insider confidence versus corporate optimism.
Laura Fernández, former chief of staff to President Rodrigo Chaves, holds a commanding lead and could secure an outright victory, promising to double down on the incumbent's hardline security agenda.
Israel has reopened the Rafah border crossing between Gaza and Egypt for limited pedestrian movement, a move long demanded by aid agencies. However, the crucial flow of humanitarian supplies remains restricted, and the reopening follows deadly violence in the area.
As Amgen prepares to release its fourth-quarter results, investors are watching for signs of sustained momentum in its key drug portfolios and the impact of recent acquisitions.
Venezuela's government has unveiled a draft amnesty law that could free hundreds of detainees, while announcing the conversion of the infamous Helicoide detention center—long accused of abuses—into a sports and social services facility.
Amneal Pharmaceuticals' shares have surged over 64% in the past year, prompting investors to question if the rally still has room to run. A closer look at valuation metrics suggests the generic drugmaker may still be trading at a significant discount to its intrinsic value.
Regeneron Pharmaceuticals reported a steady finish to 2025, driven by growth in key drugs Dupixent and EYLEA HD. While navigating competitive pressures on its legacy blockbuster, the biotech giant outlined an ambitious 2026 strategy focused on regulatory milestones and a broad clinical pipeline.
After a three-year suspension due to insurgent violence, TotalEnergies and Mozambique have agreed to restart one of Africa's largest natural gas developments, raising hopes for economic transformation amid lingering risks.
Lawmakers are negotiating a short-term deal to fund the Department of Homeland Security, aiming to avoid a partial government shutdown this weekend. The talks occur against the backdrop of heightened political pressure following recent violence in Minneapolis and a shift in the administration's enforcement rhetoric.
